Excelerate Health Ventures LLC
Emerging managerSEC exempt reporting adviser (venture capital exemption).
- Website
- https://exceleratehealth.com
- HQ
- NC
Excelerate Health Ventures LLC invests exclusively in Pharma Tech, B2B SaaS and tech-enabled services with capital-efficient models built to scale. Its newest fund focuses on AI-powered Pharma Tech and tech-enabled pharma services for early-stage companies, and its initial closing was announced in April 2026. Earlier funds backed capital-efficient healthcare software companies across provider, payer, and pharma markets.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Seed, Series A | Not enough dated deals | Series A, Series B |
| Sectors | Enterprise SaaS, Healthtech | Not enough dated deals | Healthtech, Data analytics |
| Regions | US | Not enough dated deals | NC, MA |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2014 | 1 | Edtech, Healthtech, Media |
| 2015 | 3 | Healthtech, Data analytics, Fintech |
| 2016 | 3 | Healthtech, Data analytics, Enterprise SaaS |
| 2017 | 3 | Healthtech, Data analytics, Logistics |
| 2018 | 5 | Healthtech, Biotech, Edtech |
| 2019 | 3 | Healthtech, Biotech, Data analytics |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2014 | 0 | 0 | 0 | 1 | 0 |
| 2015 | 0 | 0 | 1 | 0 | 0 |
| 2016 | 0 | 0 | 2 | 0 | 0 |
| 2017 | 0 | 1 | 1 | 1 | 0 |
| 2018 | 0 | 1 | 0 | 1 | 0 |
| 2019 | 0 | 0 | 2 | 0 | 1 |
| 2020 | 0 | 0 | 0 | 0 | 0 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Excelerate Health Ventures III LP Invests in Pharma Tech, B2B SaaS and tech-enabled pharma services, with a focus on AI-powered pharma technology. Backs capital-efficient models built to scale, typically at seed and Series A stages, often leading or co-leading rounds. Inferred from the firm's website | 2026 | $21.85M (Form D) | Raising |
| Excelerate Health Ventures II LP | 2021 | $35M to $39.56M (Form D and SEC adviser filing) | Follow-ons only |
03 · People across funds
- Andrew Schwab, Managing Partner of the Manager of the General Partner of the Issuer
Excelerate Health Ventures III LP (Named on Form D); Excelerate Health Ventures II LP (Named on Form D)
- B. Bahram, Managing Partner of the Manager of the General Partner of the Issuer
Excelerate Health Ventures III LP (Named on Form D); Excelerate Health Ventures II LP (Named on Form D)
- Maulik Mehta, Manager of the Manager of the General Partner of the Issuer
Excelerate Health Ventures III LP (Named on Form D)
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://exceleratehealth.com
- https://exceleratehealth.com/founders/
- https://exceleratehealth.com/approach/
- https://exceleratehealth.com/portfolio/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026